Dyax’s discovers, develops and commercialize innovative biopharmaceuticals for unmet medical needs. Dyax’ therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax focuses on oncology and inflammation. Its discovery technology provides it with the capability of identifying and developing its own clinical leads. 

 The company was co-founded in 1995 by biotechnology entrepreneur Henry E. Blair, presently the Chairman, President and Chief Executive Officer of Dyax Corp. Dyax Corp. was formed by the merger between Biotage, a separations instrument chromatography firm, and Protein Engineering Corporation, from which it acquired its patented proprietary phage display technology. In 2003, Dyax sold its non-core business, Biotage, to focus exclusively on biotherapeutics.

Dyax Corp. issued an initial public offering (IPO) in August 2000 and is listed on the NASDAQ exchange (Ticker: DYAX). It is headquartered in Cambridge, Massachusetts.

Technology

Dyax’s core proprietary phage display technology allows for the rapid identification of compounds that bind with very high affinity and specificity to therapeutic targets. Utilizing phage display, the firm generates large diverse libraries of human antibodies, peptides, and proteins, which may be screened against disease-associated target molecules to identify potential binders. Automation allows it to rapidly screen these libraries for high-affinity binders. The firm’s libraries’ vast size and diversity often yield multiple candidates, from which we can quickly select the single best therapeutic candidate.

Results

Dyax’s lead product candidate is DX-88, a recombinant small protein that has two separate indications; Hereditary angioedema (HAE) and prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures.

In April 2008, Dyax licensed to Cubist Pharmaceuticals the intravenous formulation of DX-88 for surgical indications in North America and Europe.  Cubist is responsible for the ongoing development of DX-88 in this indication..

In The News

Dyax Announces DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA4(R)) 

FORWARD-LOOKING STATEMENT: Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD").